Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
Overview of INmune Bio Inc
INmune Bio Inc (NASDAQ: INMB) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies. With a unique commitment to harnessing the patient’s innate immune system, the company’s approach is grounded in precision medicine and innovative biological mechanisms. By targeting key drivers of immune dysfunction, INmune Bio aims to address complex and life-threatening conditions in oncology, neurodegenerative diseases, and chronic inflammation.
Core Business and Value Proposition
At its core, INmune Bio concentrates on reprogramming the body’s natural defense mechanisms to combat disease. The company operates two major product platforms, each designed to tackle distinct pathological processes:
- The Dominant-Negative TNF (DN-TNF) Platform: This platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor (sTNF) without interfering with trans-membrane TNF or TNF receptors. This selective inhibition aims to alleviate chronic inflammation and restore normal immune function. Product candidates within this platform are being assessed in clinical trials for conditions such as cancer, early Alzheimer’s disease, and treatment-resistant psychiatric disorders.
- The Natural Killer (NK) Cell Priming Platform: INKmune, the flagship product of this platform, employs a pharmaceutical-grade, replication-incompetent human tumor cell line to prime resting NK cells into tumor killing memory-like NK cells. This therapy is designed to eliminate residual malignant cells by enhancing the cytotoxic function of NK cells, particularly in a hostile tumor microenvironment where conventional therapies may fall short.
Scientific Foundations and Mechanism of Action
INmune Bio’s approach is deeply rooted in immunology and cellular biology. By targeting the innate immune system, the company seeks to modulate critical pathways that drive chronic disease. The DN-TNF platform focuses on the inflammatory cascade by reducing soluble TNF levels, which may contribute to neuroinflammation and cancer progression. In parallel, the INKmune platform provides multi-channel activation signals to NK cells, thereby converting them into potent, long-lived effectors capable of recognizing and eliminating a broad spectrum of tumors.
Clinical Development and Pipeline
The company’s pipeline is robust and comprehensive, with multiple product candidates under clinical evaluation. The development strategy emphasizes the use of precision medicine techniques tailored to patient-specific biomarkers. Candidates such as INKmune, XPro™, and INB03 are undergoing various stages of clinical trials in diseases ranging from metastatic cancers to early Alzheimer’s disease. Each clinical program is designed to validate the therapeutic potential through a mechanism of action that addresses the underlying pathology at a cellular level.
Market Position and Competitive Landscape
Despite operating in a field characterized by intense competition and rapid scientific advances, INmune Bio differentiates itself with its dual-platform approach and commitment to leveraging both innate immune modulation and precision medicine. While many biotechnology companies focus on a single therapeutic area or mechanism, INmune Bio’s diversified pipeline offers a multi-pronged strategy to tackle residual and treatment-resistant disease. This positioning is integral to its strategy to fill gaps in current treatment paradigms.
Precision Medicine and Patient-Centric Approach
INmune Bio’s research and development are anchored in the principles of precision medicine. By identifying patients with specific biomarkers indicative of immune dysfunction, the company aims to tailor its therapies for maximal efficacy. This patient-centric focus is supported by rigorous clinical trial designs that yield detailed insights into immunologic responses, enhancing the overall therapeutic index of its investigational products.
Clinical Trial Design and Regulatory Environment
The company’s clinical trials are structured to meet high standards of scientific rigor and regulatory compliance. With trial methodologies that integrate novel endpoints and advanced biomarker assessments, every study is designed to generate reproducible and meaningful data. Although all clinical data are subject to the uncertainties inherent in early-stage research, INmune Bio’s protocols underscore its commitment to safety and efficacy without resorting to time-sensitive claims.
Scientific Collaboration and Expertise
INmune Bio benefits from close collaborations with academic institutions, leading clinical researchers, and renowned experts in neuropsychology and immunology. These partnerships reinforce the company’s technical expertise and provide a foundation for its complex therapeutic strategies. The cross-disciplinary collaboration helps ensure that each investigational product is backed by robust preclinical data and a thorough understanding of the underlying disease mechanisms.
Conclusion
In summary, INmune Bio Inc represents a sophisticated and methodical approach to addressing unmet medical needs through innovative immunotherapy solutions. By leveraging two distinct but complementary product platforms, the company works at the intersection of oncology, immunology, and neuroscience. Its rigorous clinical trial programs, focus on precision medicine, and deep-rooted scientific expertise have positioned it as an important player in the evolving landscape of clinical-stage biotechnology. The comprehensive strategy adopted by INmune Bio is a testament to its mission to harness the innate immune system to fight disease in a targeted, efficient, and ultimately patient-friendly manner.
INmune Bio (NASDAQ: INMB) will present data on INKmune™ therapy for patients with MDS or AML at the American Society for Hematology Conference in New Orleans, from December 10-13. The study, conducted at Southampton University, shows INKmune's safety in 4 patients and indicates sustained NK cell activation in 3. Notably, one patient exhibited long-lasting tumor-killing memory-like NK cells. The trial continues to enroll participants in the UK and EU, with plans to expand to the US for solid tumor indications. Key cytokines associated with immune responses were significantly altered post-treatment.
On December 6, 2022, INmune Bio presented findings at the 45th San Antonio Breast Cancer Symposium, highlighting the combination of INB03™ and trastuzumab-deruxtecan for treating HER2+ breast cancer. This combination could reverse resistance to HER2-targeted therapies, enhancing treatment efficacy and reducing toxicity. MUC4, a biomarker of resistance, is downregulated by INB03™, which improves anti-tumor immune responses. Key results showed significant tumor growth inhibition when INB03™ was included, with no added toxicity. This may lead to further immunotherapy opportunities for patients resistant to existing treatments.
INmune Bio will participate in the 15th CTAD Conference from November 29 to December 2 in San Francisco. The company is focused on developing therapies targeting Alzheimer's Disease (AD) through an innovative Phase 2 program using novel biomarkers and strategic trial design. Their XPro™ treatment aims to halt the progression of AD by utilizing unique patient criteria, cutting-edge neuroimaging technologies, and an effective cognitive endpoint called EMACC. INmune believes that their approach will surpass traditional anti-amyloid therapies.
INmune Bio has received a "No Objection Letter" from Health Canada to commence its Phase II trial using XPro1595 for mild Alzheimer’s Disease. This approval enables patient enrollment in Canada, joining ongoing efforts in Australia and awaiting clearance from the FDA for U.S. participation. The first patient has finished dosing and is enrolled in an extension study. XPro1595 works by inhibiting soluble tumor necrosis factor, potentially reducing neuroinflammation and improving cognition in patients.
INmune Bio reported its Q3 2022 financial results, showing a net loss of approximately $7.7 million, down from $9.5 million in Q3 2021. R&D expenses decreased to $5.2 million from $6.5 million year-over-year. The FDA is reviewing a clinical hold on XPro1595 trials for Alzheimer’s Disease, while patient enrollment for the Phase 2 trial is ongoing in Australia. Positive data was shared regarding the INKmune platform's efficacy against solid tumors. The company holds approximately $57.4 million in cash as of September 30, 2022, with 17.9 million shares outstanding.
INmune Bio (NASDAQ: INMB) announced it will host a conference call on November 2, 2022, at 4:30 PM ET to discuss its third-quarter results for the period ended September 30, 2022. The call will provide important updates on the company’s clinical-stage immunology treatments, which focus on harnessing the innate immune system to combat diseases. Notable products, INB03™ and XPro™, are under clinical trials targeting cancer and neurodegenerative diseases. Investors can join via a [live audio webcast](https://www.globenewswire.com/Tracker?data=jni87MnRMi1SJ_fIn5KPNuQg5GFixjb5sEr92-ts9gQK1hhT6EDFSgA5BW2IybxjB_Tm96tsj81J07gj9mqa9mt5ZJ8XnV4lpwJxNdPaMwjg_Mwg2krbA9nimtaw6G69hAyfAcvTnGgZvtVR28TJ4vntC84o5VjjX1he2ny1ornTKsLLXqYj5RBDX9RwiILUPZ5r9UnWt1Ab2gBWySFf1nxecypEkzIeqBqTe7zjRUU=).
INmune Bio, Inc. (NASDAQ: INMB) presented promising data on INKmune, a treatment aimed at solid tumors, at the Innate Killer Summit Europe on October 19, 2022. Solid tumors account for 90% of adult cancers, yet most therapies target liquid tumors. INKmune enhances the ability of Natural Killer (NK) cells to attack NK-resistant cancer types, including prostate, ovarian, renal, and nasopharyngeal cancers. Notably, INKmune-primed NK cells showed a 66% lysis rate on DU145 prostate cells compared to less than 4% for unprimed cells. This data supports the transition of INKmune trials towards solid tumors, potentially benefiting over 4 million patients in the US.
INmune Bio (NASDAQ: INMB) announced that RJ Tesi, M.D., CEO, will present at two upcoming conferences: the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 4:00 pm ET in New York, and the Baird Global Healthcare Conference on September 14, 2022, at 3:45 pm ET. Both events will include one-on-one meetings with management. The company focuses on creating treatments that leverage the innate immune system against diseases, with products in clinical trials targeting multiple conditions.
INmune Bio reported its Q2 2022 financial results and business update, highlighting the dosing of the first patient in a Phase II trial for Alzheimer’s using XPro™. The FDA review concerning a clinical hold on XPro1595 is ongoing. The company has sufficient doses for ongoing trials and has presented promising data on XPro™ and INB03 at various conferences. Financially, INmune posted a net loss of $6.8 million, slightly up from $6.7 million last year, with $61.2 million in cash as of June 30, 2022. Shares outstanding are approximately 17.9 million.
INmune Bio, Inc. will host a conference call on August 3, 2022 at 4:30 PM ET to discuss its Q2 2022 results and provide a corporate update. Participants can join by dialing 1-877-407-0784 (or 1-201-689-8560 internationally) and entering conference ID 13728540. The live webcast will also be available. INmune Bio focuses on developing therapies targeting the innate immune system for diseases such as cancer and Alzheimer's.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
What is the core focus of INmune Bio Inc?
How does the DN-TNF platform work?
What is the mechanism behind INKmune™?
What diseases are INmune Bio’s products targeting?
How does INmune Bio integrate precision medicine?
What distinguishes INmune Bio from other biotech companies?
Are INmune Bio’s therapies tumor agnostic?
What is the regulatory status of their product candidates?
